NeuroKaire picks the right antidepressant by reading a blood sample
The Series A precision-psychiatry company, already covered by Medicare and Medicaid, is one of 21 startups selected for ScaleUp House's inaugural cohort.
NeuroKaire is one of the companies selected for the inaugural ScaleUp House cohort, joining the year-round program as it enters its next stage of international growth. The company develops a precision psychiatry platform that uses a blood draw to guide prescribers to the right antidepressant for each patient, with a focus on expanding its presence in global markets and building the foundations for its next phase of growth.
ID card
- Name: NeuroKaire
- Industry: MedTech
- Current Stage: A
- Founder Name: Talia Cohen-Solal
- Year Founded: 2018
- Number of Employees: 23
Company Description
NeuroKaire is a precision psychiatry platform offering insight into each patient's brain through a simple blood draw. Its first test, BrightKaire, guides prescribers to the right antidepressant for each patient. By combining biology, computer vision and AI, BrightKaire identifies the best antidepressant for each patient with, according to the company, 84.6% accuracy. It is a "brain-in-a-dish" technology approved for routine clinical testing (US and EU) and is covered under Medicare and Medicaid. NeuroKaire addresses a $20B U.S. TAM, scaling through telemedicine partners, enterprise health brokers, and value-based care networks, with pharmaceutical collaborations and expansion planned into ADHD and anxiety.
